Advertisement
Singapore markets open in 2 hours 33 minutes

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    64,140.61
    -2,253.24 (-3.39%)
     

  • CMC Crypto 200

    1,390.42
    -33.68 (-2.37%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Gold

    2,330.20
    -8.20 (-0.35%)
     

  • Crude Oil

    82.88
    +0.07 (+0.08%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Company News for Jan 10, 2023

Zacks Equity Research
·1-min read

  • Shares of Regeneron Pharmaceuticals Inc. REGN plummeted 7.7% after the company declared that sales of its Eylea drug were negatively impacted in fourth-quarter 2022 due to pressure from an off-label competitor.

  • Shares of Lululemon Athletica Inc. LULU plunged 9.3% after the company reported that its gross margin has shrank in fourth-quarter 2022.

  • Duck Creek Technologies Inc. DCT shares soared 46.5% after the company said that private equity firm Vista Equity Partners will acquire it for $19 per share.

  • Baxter International Inc. BAX shares tumbled 7.7% after the company announced that it will spin off its kidney care business to restructure the company.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Baxter International Inc. (BAX) : Free Stock Analysis Report

lululemon athletica inc. (LULU) : Free Stock Analysis Report

Duck Creek Technologies, Inc. (DCT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research